	Application No.	Applicant(s)	
Notice of Allowability	10/077,130 Examiner	KAPELLER-LIBERMANN ET AL.  Art Unit	
	Examiner	Art Onit	
	Maryam Monshipouri	1652	
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.			
1. This communication is responsive to			
2. The allowed claim(s) is/are 1-7,12 and 18.			
3. The drawings filed on are accepted by the Examiner.			
<ul> <li>4. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). <ul> <li>a) ☐ All b) ☐ Some* c) ☐ None of the:</li> <li>1. ☐ Certified copies of the priority documents have been received.</li> <li>2. ☐ Certified copies of the priority documents have been received in Application No</li> <li>3. ☐ Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* Certified copies not received:</li> </ul> </li> <li>Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.</li> <li>THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.</li> <li>5. ☐ A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.</li> <li>6. ☐ CORRECTED DRAWINGS ( as "replacement sheets") must be submitted.  <ul> <li>(a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached</li> <li>1) ☐ hereto or 2) ☐ to Paper No./Mail Date</li> <li>(b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of</li> </ul> </li> </ul>			
Paper No./Mail Date  Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).			
7. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.			
Attachment(s)  1. Notice of References Cited (PTO-892)  2. Notice of Draftperson's Patent Drawing Review (PTO-948)  3. Information Disclosure Statements (PTO-1449 or PTO/SB/0: Paper No./Mail Date  4. Examiner's Comment Regarding Requirement for Deposit of Biological Material	5. Notice of Informal Pa 6. Interview Summary Paper No./Mail Date 8), 7. Examiner's Amendm 8. Examiner's Stateme 9. Other	(PTO-413), e nent/Comment	

Serial Number: 10/077,130

Art Unit 1652

An **Examiner's Amendment** to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this Examiner's Amendment was given in a telephone interview with Mr. Mario Cloutier, on 5/10/2005.

## **Examiner's Amendment to the Claims**

In claim 18, line 1, delete "a compound which selectively hybridizes to a "and substitute therefor --- the ---.

In claim 1(b), after SEQ ID NO:5", delete ";", and substitute therefor --- . ---.

## **Examiner's Amendments to the Specification**

The following is an **Examiner's Statement of Reasons for Allowance**:

Claims 1-7, 12 and 18 are directed to isolated nucleic acid molecules comprising DNA sequences encoding either a human protein kinase of specific amino acid sequence or homologs thereof having at least 95% identity to said amino acid sequence with kinase activity, vectors, kits and host cells comprising said molecules and methods of expressing said molecules.

Claimed DNA sequences are free of prior art. Further the prior art does not teach or suggest preparing such specifically claimed DNA sequences. Hence, said DNA sequences are also novel and non-obvious.

Serial Number: 10/077,130

Art Unit 1652

Since claimed DNA sequences are both novel and non-obvious, molecules comprising said sequences, vectors, kits and host cells comprising said molecules and methods of expressing said molecules are also novel a d non-obvious.

Claims 1-7, 12 and 18 are allowed.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Maryam Monshipouri whose telephone number is (571) 272-0932. The examiner can normally be reached on 7:00 a.m to 4:30 p.m. except for Mondays.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ponnanthapu Achutamurthy can be reached on (571) 272-0928. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306 or (571)273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Maryam Monshipouri Ph.D.

Primarey Examiner